Makoto Shimomura

Adenosquamous carcinoma of the liver: case report

We report a case of adenosquamous carcinoma of the liver arising from the left intrahepatic bile duct. A 65-year-old man was referred to our hospital with epigastric discomfort of 2 weeks duration. The results of laboratory and clinical investigations suggested the presence of a cholangiocarcinoma; consequently, left hepatectomy with caudate lobectomy were performed. The histopathological examination revealed adenocarcinoma, squamous carcinoma, and transitional cancer cells in the resected specimen. Multiple liver metastases developed 12 months after surgery, leading to hepatic insufficiency 3 months later. Twenty-five cases of adenosquamous carcinoma of the liver reported in the world literature, including the present case, were reviewed as to the clinicopathological features.

Inhibitory Effect of Loxiglumide (CR 1505), a CholecystokininReceptor Antagonist, onN-Nitrosobis(2-oxopropyl)amine-induced BiliaryCarcinogenesis in Syrian Hamsters

We evaluated the cholecystokinin (CCK)receptor antagonist loxiglumide (CR1505) for a possible inhibitoryeffect on biliary carcinogenesis in a hamster model. Experimental groupI underwent cholecystoduodenostomy and ligation of the distal end ofthe common bile duct, after which the animals were injected withN-nitrosobis(2-oxopropyl)amine (BOP) alone. Group II, afterthe same surgical procedure as in group I, were given injections of BOPand then given loxiglumide in their diet. The sham-operated groupunderwent simple laparotomy and then were given injections of BOP.Loxiglumide significantly inhibited BOP carcinogenicity in thegallbladder and extrahepatic bile duct but not in the intrahepatic bileducts or pancreas. Autoradiography showed that loxiglumidesignificantly suppressed 125I-Bolton-Hanter (BH)-CCK-8binding to CCK receptors in the gallbladder and extrahepatic bile ductbut not in the liver or pancreas, and CCK binding to its receptors wasobserved in an area identified as cancer tissue. CCK receptorantagonists have an inhibitory effect on BOP carcinogenesis in theextrahepatic biliary tract, including the gallbladder and extrahepaticbile duct, of Syrian hamsters. The difference in the inhibitory effectof loxiglumide on biliary carcinogenesis in hamsters according to sitemay be due to differences in CCK receptors or the affinity ofloxiglumide for such biliary tract organs. A difference betweencarcinogenesis in the intrahepatic bile ducts and extrahepatic biliarytract may be another reason.